Acadia Pharmaceuticals (ACAD) Gross Profit (2016 - 2026)

Acadia Pharmaceuticals' Gross Profit history runs 11 years deep, the most recent figure standing at $243.3 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 8.64% year-over-year to $243.3 million in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 9.25% increase from a year earlier, with the FY2025 full-year figure at $982.5 million, up 12.16% from the prior year.
• Gross Profit slipped to $243.3 million in Q1 2026 per ACAD's latest filing, from $257.8 million in the prior quarter.
• Across five years, Gross Profit topped out at $257.8 million in Q4 2025 and bottomed at $112.5 million in Q1 2022.
• The 5-year median for Gross Profit is $213.2 million (2023), against an average of $193.7 million.
• Across the five-year window, Gross Profit grew 0.51% in 2022 and soared 58.98% in 2023, its largest moves.
• Year by year, Gross Profit stood at $134.1 million in 2022, then jumped by 58.98% to $213.2 million in 2023, then gained by 11.56% to $237.8 million in 2024, then grew by 8.4% to $257.8 million in 2025, then fell by 5.62% to $243.3 million in 2026.
• Per Business Quant, the three latest ACAD Gross Profit figures stand at $243.3 million (Q1 2026), $257.8 million (Q4 2025), and $257.0 million (Q3 2025).